Skip to main content

Ipilimumab and serous retinal detachment

Medicines Safety Update

Related content

  • Sertraline and microscopic colitis

    Health professionals are advised that the Product Information (PI) documents for sertraline have been updated to include microscopic colitis as a potential adverse effect of unknown frequency based on post-marketing experience.
  • Ocrelizumab and late onset neutropenia

    The Product Information for ocrelizumab has been updated to include a warning and further information about late onset neutropenia.

Help us improve the Therapeutic Goods Administration site